Exercise of Share Options

RNS Number : 1485G

Alliance Pharma PLC

06 May 2011

 



For immediate release

6 May 2011

 

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

Exercise of Share Options and Directors' Shareholdings

Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, announces that the Company was notified today that on 6 May 2011 Tony Booley, a Director of the Company, exercised options to acquire 1,110,000 ordinary shares of 1 pence each in the Company ("Ordinary Shares") at a price of 8.5p per share, which were subsequently all sold on 6 May 2011 at 33 pence per share.  Following these transactions, Mr Booley holds 6,810,723 Ordinary Shares in the Company, representing approximately 2.85% of the issued share capital.

Application has been made for the 1,110,000 Ordinary Shares to be admitted to AIM, with trading expected to commence on 12 May 2011 ("Admission").  Upon Admission, the new Ordinary Shares will rank pari passu in all respects with the existing Ordinary Shares of the Company.

The Company also announces that it was informed today that John Dawson, a Director of the Company, has sold 2,250,000 ordinary shares of 1p each in the Company ("Ordinary Shares") at a price of 33 pence per share.  Mr Dawson's beneficial interest is now 40,011,402 Ordinary Shares, representing 16.73% of the Company's issued share capital.

Mr Dawson also has a non-beneficial interest in 20,000,000 shares, representing 8.36% of the Company's issued share capital.  Mr Dawson's combined beneficial and non-beneficial interest is now 60,011,402 shares, representing 25.09% of the issued share capital of the Company.

Following the exercise of the options, Alliance will have 239,135,915 Ordinary Shares in issue.

For further information:

Alliance Pharma plc	+ 44 (0) 1249 466966
John Dawson, Chief Executive Officer
Richard Wright, Finance Director
www.alliancepharma.co.uk
Buchanan Communications	+ 44 (0) 20 7466 5000
Mark Court / Jessica Fontaine
Numis Securities Limited	+ 44 (0) 20 7260 1000
Nominated Adviser: Michael Meade / Simon Blank
Corporate Broking: David Poutney

Notes to editors:

About Alliance

Alliance, founded in 1998, is an AIM listed speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has a strong track record of acquiring the rights to established niche products and, following the Cambridge Laboratories acquisition, owns or licenses the rights to more than 50 pharmaceutical products and continues to explore opportunities to expand the range.

Alliance's products are prescribed in the treatment of a wide range of conditions and include products used in the treatment of dermatological conditions, in oncology, in childbirth, in the prevention of heart disease, in Parkinson's disease, in nutrition and in nasal infections.  Alliance's sales are mainly prescription driven.  Its products are distributed to hospitals directly and to pharmaceutical wholesalers, which service both hospital and retail pharmacies with their prescription requirements.

Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.

 

END

 

 

RDSLLFEEERIRIIL